Humacyte said today that it landed a $14.1 million award from the California Institute for Regenerative Medicine to support a clinical trial comparing its human acellular vessel, Humacyl, to arteriovenous fistulas – the traditional way to create vascular access in patients who need hemodialysis.
The Research Triangle Park, N.C.–based company said it plans to evaluate Humacyl as a conduit for hemodialysis in a group of patients with end-stage renal disease who need renal replacement therapy.